Thanks to John O’Brien and NPC, I had the privilege of recently participating on a panel at the AVBCC meeting in NYC with Beth Hamilton from Astra Zeneca. The panel was a discussion of ex-U.S. drug access and pricing and how it could impact MFN in the U.S.
I wanted to share with you just a few of my comments:

Read More

Thank you for your interest in our content. Registering allows you to access a wide range of informative articles, briefs, and whitepapers throughout the site.

Privacy is important. We do not share registrant information with anyone outside of Numerof & Associates. For details, please see our Privacy Policy. Subscribers to our mailings can unsubscribe instantly at any time.

×